COYA — Coya Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1835022 ·
Last close
$3.02
Market Cap
$70.84M
52W High
$6.62
52W Low
$2.72
ADV30
170,209
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 234,134 | — | -10,948,601 | -10,617,741 | 39,317,729 | 35,802,136 | 5,749,383 |
| Jun 2026 | 243,745 | — | -7,046,988 | -6,638,260 | 47,308,078 | 43,181,002 | 4,032,067 |
| Mar 2026 | 251,147 | — | -7,640,217 | -7,206,990 | 53,271,099 | 50,724,643 | 4,300,739 |
| Dec 2025 | 3,959,999 | — | -6,030,888 | -5,708,542 | 49,950,245 | 46,822,786 | 6,922,015 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,826,758
Investing CF
$-1,558,502
Financing CF
$31,057,530
CapEx
$-23,240
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.18
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-86,426,268
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-31,666,694
Pretax Income TTM
$-30,168,444
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,689,025
EBITDA
$-29,842,930
Free Cash Flow
$-13,559,663
Enterprise Value
$37,620,932
Total Cash
$35,802,136
Total Debt
$0
Shares Out
23,457,849
Trailing EPS
$-1.39
Book Value
$1.43
ROE
-99.2%
ROA
-52.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,945,753 | -22,555,225 | -21,226,107 | 49,950,245 | 6,922,015 | 43,028,230 | -10,739,301 |
| Dec 2024 | 3,554,061 | -17,249,711 | -14,880,787 | 44,347,016 | 4,769,921 | 39,577,095 | -10,288,822 |
| Dec 2023 | 6,002,206 | -7,903,349 | -7,987,836 | 41,262,274 | 5,626,665 | 35,635,609 | -11,188,811 |
| Dec 2022 | 0 | -9,811,939 | -12,244,776 | 8,395,566 | 16,789,111 | -8,393,545 | -7,239,354 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$8,019,145
NetIncome TTM
$-21,669,623
OpCashFlow TTM
—
Assets (Latest)
$47,308,078
Forward EPS
$-2.02
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $3.09 · call volume: 6 · put volume: 221
Expected Move to 2027-02-19:
±$2.75
(89.00%) —
implied range
$0.34 –
$5.84
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZYBT | Zhengye Biotechnology Holding Ltd | $72.03M | $1.52 | — |
| VTVT | vTv Therapeutics Inc. | $69.36M | $17.29 | — |
| MNOV | MEDICINOVA INC | $68.65M | $1.34 | — |
| CING | Cingulate Inc. | $68.64M | $4.72 | — |
| GOSS | Gossamer Bio, Inc. | $67.52M | $11.04 | — |
News headlines (Yahoo Finance, 1h cache)
Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
2026-11-10 13:00 · Yahoo
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual
2026-10-28 12:00 · Yahoo
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
2026-10-14 12:00 · Yahoo
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
2026-10-13 12:00 · Yahoo
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
2026-09-08 12:00 · Yahoo
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
2026-06-08 12:00 · Yahoo
Coya Therapeutics secures FDA fast track status for COYA 302
2026-05-14 11:15 · Yahoo
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
2026-06-15 12:00 · Yahoo
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
2026-10-05 12:00 · Yahoo
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
2026-09-15 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.